VITRUVIAE Presents CAR T Immunotherapy At AACR 2025

Vitruviae Inc. is pleased to announce the publication of preclinical data demonstrating the promising efficacy of our innovative Man9xPS-CAR T cell immunotherapy targeting pancreatic cancer. Presented at the AACR Annual Meeting and published in Cancer Research (Abstract LB028), this cutting-edge approach harnesses a CAR T that specifically recognizes a unique cancer-associated glycan and lipid signature, enabling precise targeting of pancreatic tumor cells while sparing healthy tissue.

The results show robust anti-tumor activity in vivo, highlighting the potential of this therapy to address the unmet need in pancreatic cancer treatment. These findings support continued development towards clinical evaluation, bringing us closer to delivering next-generation, highly specific immunotherapies for patients with pancreatic cancer.

Read the full abstract here.